In several hematological malignancies such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and myelodysplastic syndrome, TP53 status is used to identify patients likely to benefit from specific treatment1,2. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.